Cargando…
Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic-Pharmacodynamic Behavior: An Example Using 5-Lipoxygenase Inhibitors
Zileuton, a 5-lipoxygenase (5LO) inhibitor, displays complex pharmaokinetic (PK)-pharmacodynamic (PD) behavior. Available clinical data indicate a lack of dose–bronchodilatory response during initial treatment, with a dose response developing after ~1–2 weeks. We developed a quantitative systems pha...
Autores principales: | Demin, O, Karelina, T, Svetlichniy, D, Metelkin, E, Speshilov, G, Demin Jr, O, Fairman, D, van der Graaf, P H, Agoram, B M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026633/ https://www.ncbi.nlm.nih.gov/pubmed/24026253 http://dx.doi.org/10.1038/psp.2013.49 |
Ejemplares similares
-
Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach
por: Karelina, Tatiana A, et al.
Publicado: (2012) -
A Mathematical Modeling Approach to Understanding the Effect of Anti‐Interleukin Therapy on Eosinophils
por: Karelina, T, et al.
Publicado: (2016) -
Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models
por: Agoram, B
Publicado: (2014) -
A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain
por: Benson, N, et al.
Publicado: (2014) -
A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human
por: Karelina, T, et al.
Publicado: (2017)